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South Africa (SA) is experiencing a dramatic rise in 
the use of methamphetamines, particularly in the 
Western Cape Province.[1] The drug is commonly 
used by young people of mixed ancestry,[2] and 
particularly those of lower socioeconomic status 
and educational level.[3] A closely related amphetamine, known as 
Ecstasy, was initially used as an appetite suppressant but rapidly 
became a recreational drug used in dancing clubs, where it was 
found to cause hyperthermia, dehydration and rhabdomyolysis, 
and an increased risk of acute renal failure.[4] Methamphetamine 
is relatively easy and inexpensive to produce, making it readily 
accessible.[5]
The use of amphetamines is associated with significant adverse 
physical effects. The toxic effects include cardiomyopathy,[6] 
ischaemic heart disease, aneurysm formation, seizures, psychosis, 
hallucinations, stroke,[7] hyperthermia, rhabdomyolysis, pulmonary 
hypertension, systemic hypertension, acute renal failure[8] and 
hepatocellular damage.[9] A review of the histopathological findings 
in drug users does not mention any renal effects in amphetamine 
users.[10] There have been isolated reports of adverse renal effects 
including necrotising renal vasculopathy,[8] an exaggerated decline 
in renal function over 15-year follow-up of patients who used 
methamphetamines,[11] an increased serum creatinine level 1 year 
after transplant in recipients of kidneys from donors who had used 
methamphetamines,[12] and early graft loss of two kidneys from 
donors who had used methamphetamines.[13]
In Africa there is even less information on the health outcomes of 
methamphetamine use. What literature there is addresses the dental, 
psychiatric and social impact of drug use in SA, particularly in the 
Western Cape.[14-16]
This study reviewed patients attending a single tertiary hospital 
with hypertension and/or chronic kidney disease (CKD) and who 
reported the use of methamphetamines.
Methods
Patients with a history of methamphetamine use who were referred 
to the Division of Nephrology and Hypertension at Groote Schuur 
Hospital, Cape Town, for evaluation were retrospectively studied 
from their medical records from 2005 to 2013. Patient demographics, 
biophysical parameters, blood pressure, renal function, renal 
ultrasound and biopsy findings, complications of CKD defined in 
terms of the Kidney Disease: Improving Global Outcomes guidelines,[17] 
and comorbidities were recorded.
The estimated glomerular filtration rate was calculated using the 
Modification of Diet in Renal Disease formula (Table 1). Hypertensive 
retinopathy was graded 1 - 4 according to the presence of silver 
wiring, arteriovenous nipping, haemorrhages/exudates or papill-
oedema, respectively.[18] Malignant hypertension on fundoscopy was 
defined as grade 3 - 4 hypertensive retinopathy. Left ventricular hyper-
trophy (LVH) was defined by Sokolow-Lyon criteria of >35 mm.[19]
Renal biopsy was performed in patients with impaired renal 
function of unknown cause and/or proteinuria >3 g/d in the presence 
of normal-sized kidneys. Malignant hypertension on histology was 
defined as the presence of fibrinoid necrosis and onion-skinning of 
the arterioles associated with crenation of the glomerular basement 
membrane.
The study was approved by the University of Cape Town Research 
Ethics Committee (HREC REF: 573/2011).
Results
Forty-seven patients were identified, of whom 40 (85.1%) were 
male. Their mean (standard deviation (SD)) age was 29 (8) years. 
Table 1 shows the baseline demographics. Five patients (10.6%) were 
black Africans and the remainder (89.4%) of mixed ancestry. At the 
time of data collection, 11 patients had died, all of whom had end-
stage renal disease (ESRD) at presentation and were not eligible for 
chronic dialysis in terms of the criteria for long-term dialysis and 
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transplantation in the Western Cape;[20] all died as a consequence of 
chronic renal failure.
At presentation, 42 (89.4%) of the patients were hypertensive, 
with evidence of malignant hypertension (defined by grade 3 
or 4 hypertensive retinopathy and/or evidence on renal biopsy) 
in 21 (44.7%). The mean (SD) blood pressure was 183 (37)/114 
(24) mmHg. Significant target organ damage (TOD) as a result 
of hypertension was evident in 34 patients (72.3%). Of the 37 
patients (78.7%) who had documentation of electrocardiographic 
findings, LVH was found in 26 (70.3%). Findings on fundoscopy 
were recorded in 26 patients (55.3%): stage 1 hypertensive 
retinopathy was seen in 2 (7.7%) patients, stage 2 in 5 (19.2%), 
stage 3 in 11 (42.3%) and stage 4 in 7 (26.9%). CKD was found 
in 45 patients (95.7%). On ultrasound, 24 patients (51.1%) had 
evidence of CKD (i.e. small kidneys in 10, loss of corticomedullary 
differentiation in 4, increased echogenicity in 19). The mean (SD) 
urine protein-creatinine ratio was 0.52 (0.44) g/mmol. Twenty-six 
patients (55.3%) had stage 5 CKD, 4 (8.5%) stage 4, 4 (8.5%) stage 
3, 5 (10.6%) stage 2, and 6 (12.8%) stage 1; only 2 (4.3%) had no 
evidence of CKD.
Renal biopsy was performed in 24 patients (51.1%). Hypertensive 
changes were found in 12 biopsies (50.0%) with 6 (25.0%) showing 
malignant changes (Fig. 1, E and F). Six (25.0%) showed ESRD. 
Mesangiocapillary glomerulonephritis (MCGN) type 1 was found in 
14 biopsy cases (58.3%) (Fig. 1, A and B), all of which were positive 
for IgM and C3 complement (Fig. 1, C and D). In addition, 9 (37.5%) 
showed staining for IgG and 7 (29%) for IgA.
One individual (2.1%) tested positive for HIV, and 2 (4.3%) for 
syphilis. The HIV-positive patient underwent renal biopsy, the 
histological findings showing hypertensive changes only. No patients 
were positive for hepatitis B or C, or had infective endocarditis or 
systemic lupus erythematosus.
All the patients in this study had been using methamphetamines, 
but in only a few cases was the length of drug use documented. Some 
patients used other recreational drugs, methaqualone in 10 cases 
(21.3%) and cocaine in 3 (6.4%); no patient used intravenous drugs. 
All three patients using cocaine had malignant hypertension and 
ESRD. Two of these patients underwent renal biopsy, which showed 
hypertensive changes and ESKD in both cases, but no evidence of 
MCGN. Of the patients who had used methaqualone, 7 underwent 
renal biopsies; 6 had hypertensive changes and 5 had MCGN.
Discussion
This study investigated the association between hypertension and/
or CKD and methamphetamine use in patients referred to a single 
large tertiary hospital in Cape Town for evaluation of CKD and/or 
hypertension between 2005 and 2013. The major findings were the 
presence of severe hypertension, with 44.7% of cases complicated by 
malignant hypertension; CKD (stage 4 or 5 in 64%) was present in in 
95.7%. The unexpected and novel finding was the presence of MCGN 
in 58.3% of the 24 biopsies performed.
The association of methamphetamine use with hypertension is 
not unexpected, as the drug has vasoconstrictive properties causing 
increased systemic vascular resistance and raised blood pressure. 
However, the severity of the hypertension is remarkable. The mean 
(SD) blood pressure was 183 (37)/114 (24) mmHg, and 44.7% 
had malignant hypertension. TOD was commonly seen: 70.3% 
had LVH and 96.2% hypertensive retinopathy. On renal biopsy of 
hypertensive methamphetamine users, there were vascular changes 
of hypertension in 12 with evidence of malignant hypertension in 6.
The prevalence of CKD in this group of patients was 95.7%, with 
63.8% of patients having very severe disease (CKD stages 4 and 5). In 
the cohort, 41 cases of CKD were related to hypertension on clinical 
grounds, and this was confirmed by renal biopsy in 12 cases. The 
unexpected finding in this study was that not all cases of CKD were 
Table 1. Patient demographics
  Patients, N Mean (SD)
Age (years) 47 29.4 (8.0)
Systolic BP (mmHg) 47 183 (37)
Diastolic BP (mmHg) 47 114 (24)
BMI (kg/m2) 29 24.6 (4.4)
Creatinine (µmol/l) 47 716 (623)
Urea (mmol/l) 44 31.4 (20.1)
Potassium (mmol/l) 45 4.6 (0.88)
UPCR (g/mmol) 41 0.52 (0.44)
Haemoglobin (g/dl) 45 9.9 (2.7)
MCV (fl) 43 85 (6)
Albumin (g/l) 42 32 (9)
Cholesterol (mmol/l) 25 5.9 (2.8)
SD = standard deviation; BP = blood pressure; BMI = body mass index; UPCR = urinary 
protein-creatinine ratio; MCV = mean cell volume.
Fig. 1. Light microscopic features of kidney changes seen in methamphet­
amine users. A: Lobular glomerulus with thickened GBM (H&E); B: 
Glomerulus showing split GBM (JMS); C: Immunohistochemistry for C3 
and D, IgM subendothelial deposits; E: Concentric myointimal thickening 
(‘onion skinning’) (H&E); F: Ischaemic retraction of glomeruli with 
corrugation of the GBM (JMS). (GBM = glomerular basement membrane; 
H&E = haematoxylin and eosin; JMS = Jones methenamine silver.) 
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a consequence of hypertension. MCGN was found to be the cause in 
14 cases (58.3% of biopsies and 29.7% of the entire group). Idiopathic 
MCGN is the most common biopsy finding in Cape Town[21] and 
in other areas of SA the second most common,[22] although it is 
declining in incidence in developed countries.[23]
Known associations with MCGN did not explain the link between 
methamphetamine use and MCGN. All the biopsies that showed MCGN 
had IgM and C3 deposits, supporting chronic antigenaemia as a possible 
cause. Hepatitis C virus, hepatitis B virus, HIV, malaria and infective 
endocarditis are common infectious agents associated with MCGN, but 
these were excluded on clinical and serological grounds in all except one 
patient, who was HIV-positive. This patient had hypertensive changes on 
renal biopsy without evidence of MCGN. The two patients who tested 
positive for syphilis did not undergo renal biopsy.
MCGN is thought to result from chronic antigenaemia with 
defects in elimination or clearing of foreign antigen.[24] It is possible 
that people who use methamphetamines are exposed to multiple 
infectious antigens through the sharing of drugs and devices to 
inhale the drug. Another possible means of exposure to infectious 
antigens is through close physical contact between people during the 
process of taking the drug. It is also possible that methamphetamines 
alter self-proteins, making them immunogenic or creating haptens. 
However, these explanations are highly speculative.
On renal biopsy, MCGN and hypertension were fairly equally repres-
ented (14 and 12 cases, respectively). MCGN has a poor prog nosis, with 
50% of patients progressing to ESRD within 5 years.[24] Severe hyper-
tension (affecting 37 patients (78.7%)) also results in ESRD. Seven patients 
(14.9%) had isolated hypertension without ESRD. This suggests that there 
are at least two pathways to ESRD for patients using methamphetamines.
MCGN has been associated with intravenous drug use, especially of 
heroin.[25] However, it is unlikely that intravenous drug use was relevant 
in this group of patients; no such drug use was reported, and no patient 
was hepatitis B- or C-positive. Only one patient was found to be HIV-
positive. The prevalence of HIV in the mixed-ancestry community it is 
~5.5 - 6.6%[26] and in SA overall ~8.5%,[27] considerably higher figures 
than in this study. Similarly, hepatitis B prevalence is high in SA (~8%).[28]
Study limitations
The limitations of this study are that it is purely observational of 
the presence of hypertension, MCGN and ESRD in patients using 
methamphetamines. In addition, there is no clear pathophysiological 
pathway linking methamphetamine abuse to MCGN. Further studies, 
while difficult in the setting of illicit substances, are clearly required.
Conclusion
The abuse of methamphetamines appears to be associated with severe 
hypertension and MCGN, both of which can lead to ESRD and death. 
In a resource-limited setting, this has important implications for the 
management of these young patients. Strategies to prevent exposure 
to this easily accessible drug need to be implemented.
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